Welcome to our dedicated page for GRI Bio SEC filings (Ticker: GRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GRI Bio, Inc. (NASDAQ: GRI) SEC filings page provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-generated highlights to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on NKT cell modulators for inflammatory, fibrotic and autoimmune diseases, GRI Bio uses its filings to report on clinical progress, financing transactions, governance matters and risk factors relevant to GRI stock.
Among the most informative documents are Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, pipeline programs such as GRI-0621 for idiopathic pulmonary fibrosis and type 2 dNKT agonists for systemic lupus erythematosus, and its status as a smaller reporting and emerging growth company. These filings also summarize key agreements, intellectual property and the broader risk profile associated with clinical-stage drug development.
GRI Bio’s Form 8-K current reports highlight material events, including:
- Topline and interim data from the Phase 2a GRI-0621-IPF-02 trial in IPF, covering safety, biomarker changes, alveolar basement membrane repair markers and forced vital capacity (FVC) analyses.
- Details of public offerings of common stock, pre-funded warrants and Series F warrants, including purchase agreements, warrant terms and expected use of proceeds.
- Corporate actions such as amendments to the 2018 Equity Incentive Plan and annual meeting voting results.
On this page, users can also review registration statements on Form S-1 and amendments, which outline securities offerings and include extensive exhibit lists covering warrants, purchase agreements and other contracts. Proxy statements (DEF 14A) provide insight into board structure, compensation plans and shareholder proposals.
Stock Titan’s interface surfaces AI-powered summaries of lengthy filings to explain key points in plain language, such as how a financing may affect capital structure or how reported IPF trial data relate to GRI-0621’s development. Real-time updates from EDGAR ensure new 10-K, 10-Q, 8-K, S-1 and related forms appear promptly, while dedicated sections for insider and beneficial ownership information can be explored through the company’s broader filing history.
Use this GRI filings hub to quickly locate and interpret the regulatory documents that shape the investment narrative around GRI Bio’s NKT cell–focused pipeline and its Nasdaq-listed common stock.
GRI Bio, Inc. shareholders Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher filed an amended Schedule 13G reporting their beneficial ownership of the company’s common stock. The filing focuses on their combined position and the structure of that holding.
As of the close of business on December 31, 2025, the reporting persons may have been deemed to beneficially own 1,097,858 shares of common stock, or 9.99% of the class. This includes 229,347 shares held by Intracoastal and 868,511 shares issuable upon exercise of one warrant. The ownership percentage is based on 10,121,060 shares outstanding as of December 19, 2025 plus the warrant shares counted for this calculation.
The filing explains that additional shares are potentially issuable under several warrants but are currently blocked from exercise by provisions that cap beneficial ownership at 9.99% for one warrant and 4.99% for three others. The investors certify that the securities were not acquired for the purpose of changing or influencing control of GRI Bio.
GRO Bio, Inc. received an amended Schedule 13G from Lincoln Alternative Strategies LLC reporting that it now beneficially owns 0 shares of GRO Bio common stock, representing 0% of the class. The filer confirms it owns 5 percent or less of the company’s common stock.
Lincoln Alternative reports no sole or shared voting or dispositive power over any GRO Bio shares and certifies the securities are not held to change or influence control of the issuer. The filing formally updates regulatory records to reflect the firm’s lack of beneficial ownership.
GRI Bio, Inc. filed a current report describing that it issued a press release on February 4, 2026. The release reiterates the company’s financial results for fiscal year 2025 and summarizes key recent business highlights.
The press release is furnished as Exhibit 99.1 and is not incorporated by reference into other SEC filings or deemed filed for liability purposes.
GRI Bio, Inc. is a clinical‑stage biopharmaceutical company developing immune‑modulating therapies for inflammatory, fibrotic and autoimmune diseases, led by oral iNKT‑cell inhibitor GRI‑0621 for idiopathic pulmonary fibrosis (IPF) and dNKT‑cell agonist GRI‑0803 for lupus.
A 35‑patient Phase 2a IPF trial of GRI‑0621 met its primary safety endpoint and evaluated multiple biomarker and lung‑function measures, with no treatment‑related serious adverse events and generally manageable side effects. The company plans, subject to FDA input and additional funding, a Phase 2b study that could support conditional EU approval and potential U.S. registration.
GRI‑0803 showed disease‑modifying signals in preclinical lupus nephritis models, and the company aims to file an IND and start Phase 1a/1b studies in 2026. GRI emphasizes broad NKT‑cell biology expertise and a patent estate with expected expiries around 2032–2035.
The business remains highly dependent on raising substantial additional capital, and management has expressed substantial doubt about the company’s ability to continue as a going concern. The filing also highlights Nasdaq listing risk and previously identified material weaknesses in internal controls, only partially remediated.
GRI Bio, Inc. amended its at-the-market stock offering program with H.C. Wainwright & Co., increasing the potential aggregate offering price from
The amendment, effective as of
GRI Bio, Inc. is updating its at-the-market stock offering to permit sales of up to $60,000,000 of common stock through H.C. Wainwright & Co. as sales agent.
The company has already sold shares for an aggregate purchase price of $12,639,002.84 under the existing program. As of January 29, 2026, its public float was approximately $86.6 million, based on 1,445,015 shares of common stock held by non-affiliates. The stock last traded at $4.11 per share on the Nasdaq Capital Market on January 28, 2026.
GRI Bio, Inc. has filed a shelf registration on Form S-3 to offer up to $250,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time. Specific terms and pricing will be set in future prospectus supplements.
The company’s common stock trades on The Nasdaq Capital Market under the symbol GRI, with a last reported price of $5.55 per share on January 26, 2026. On January 23, 2026, GRI Bio effected a one-for-28 reverse stock split, and share and warrant figures in the prospectus reflect this adjustment. As of January 26, 2026, 525,358 shares of common stock were outstanding.
GRI Bio is a clinical-stage biopharmaceutical company developing therapies for inflammatory, fibrotic and autoimmune diseases. Its lead candidate, GRI-0621, targets idiopathic pulmonary fibrosis, and the pipeline also includes GRI-0803 for autoimmune disorders such as lupus and multiple sclerosis. Net proceeds from future sales under the shelf are expected to be used for general corporate purposes, including working capital and other general and administrative needs.
GRI Bio, Inc. filed a report noting that it has released additional data from its Phase 2a clinical trial of GRI-0621 in patients with idiopathic pulmonary fibrosis. The company announced these clinical findings through a press release dated January 28, 2026.
The press release is included as Exhibit 99.1, meaning the detailed trial information and outcomes are provided in that attached document rather than in the body of this report.
GRI Bio, Inc. approved a 1-for-28 reverse stock split of its common stock through a certificate of amendment to its Delaware charter. The split becomes effective at 4:01 p.m. Eastern Time on January 23, 2026, with the stock expected to begin trading on a post-split basis on The Nasdaq Capital Market on January 26, 2026.
At the effective time, every 28 issued and outstanding common shares will automatically convert into 1 share, with no change to the par value. The company will also make proportional adjustments to the exercise prices and share amounts for all outstanding stock options, warrants, convertible securities, and shares under its stock incentive plans, while keeping the total number of authorized common shares unchanged.
Shareholders who would otherwise receive fractional shares will instead get a cash payment equal to the fraction multiplied by the closing sale price of the common stock on January 23, 2026, adjusted for the reverse split. The common stock will continue to trade on Nasdaq under the symbol “GRI”.